Cerenis Therapeutics Holding Share Price Euronext Paris
Stocks
FR0012616852
Biotechnology & Medical Research
| Market Cap | 65.12M 72.88M 60.75M 55.18M 104M 7.05B 105M 730M 285M 3.59B 274M 268M 11.53B | P/E 2026 * |
-4.61x | P/E 2027 * | -4.65x |
|---|---|---|---|---|---|
| Enterprise Value | 53.92M 60.34M 50.3M 45.69M 86.05M 5.84B 86.7M 604M 236M 2.97B 227M 222M 9.54B | EV / Sales 2026 * |
12x | EV / Sales 2027 * | 5.55x |
| Free-Float |
72.26% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.31% |
| Manager | Title | Age | Since |
|---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 49 | 05/09/2019 |
| Director of Finance/CFO | - | - | |
| Chief Operating Officer | - | 31/12/2005 |
| Director | Title | Age | Since |
|---|---|---|---|
Cyrille Tupin
BRD | Director/Board Member | 49 | 05/09/2019 |
Olivier Martinez
BRD | Director/Board Member | 52 | 19/07/2010 |
Christian Chavy
BRD | Director/Board Member | 76 | 05/02/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.31% | +12.09% | - | - | 72.88M | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.68B | |
| -14.74% | -15.28% | +3.75% | +52.68% | 58.7B | |
| -1.70% | +1.75% | +4.70% | +32.96% | 48.36B | |
| +0.50% | -2.14% | +331.33% | +702.20% | 43.05B | |
| -0.72% | -3.99% | +28.50% | +29.94% | 42.48B | |
| +0.34% | -0.52% | +6.56% | +109.35% | 41.39B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.29B | |
| -0.50% | -3.10% | -10.19% | -14.35% | 23.93B | |
| -3.32% | -10.86% | -37.32% | +316.28% | 22.22B | |
| Average | -1.51% | -2.18% | +42.88% | +152.88% | 42.9B | |
| Weighted average by Cap. | -1.91% | -1.56% | +49.46% | +145.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.51M 5.04M 4.2M 3.82M 7.19M 488M 7.25M 50.52M 19.74M 248M 18.93M 18.53M 798M | 11.28M 12.62M 10.52M 9.56M 18M 1.22B 18.13M 126M 49.4M 621M 47.39M 46.36M 2B |
| Net income | -14.48M -16.21M -13.51M -12.27M -23.12M -1.57B -23.29M -162M -63.44M -798M -60.86M -59.54M -2.56B | -14.75M -16.51M -13.76M -12.5M -23.54M -1.6B -23.71M -165M -64.6M -812M -61.97M -60.63M -2.61B |
| Net Debt | -11.2M -12.53M -10.45M -9.49M -17.88M -1.21B -18.01M -126M -49.06M -617M -47.06M -46.04M -1.98B | -2.5M -2.8M -2.33M -2.12M -3.99M -271M -4.02M -28.03M -10.95M -138M -10.5M -10.28M -443M |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
